Invention Grant
- Patent Title: Multi-arm targeting anti-cancer conjugate
-
Application No.: US16498765Application Date: 2018-04-19
-
Publication No.: US11191843B2Publication Date: 2021-12-07
- Inventor: Jiandong Yuan , Yangqing Huang , Yunsong Song , Haifeng Ding
- Applicant: BrightGene Bio-Medical Technology Co., Ltd.
- Applicant Address: CN Jiangsu
- Assignee: BrightGene Bio-Medical Technology Co., Ltd.
- Current Assignee: BrightGene Bio-Medical Technology Co., Ltd.
- Current Assignee Address: CN Jiangsu
- Agency: Fish & Richardson P.C.
- Priority: CN201710263113.4 20170421,CN201710263114.9 20170421,CN201710263126.1 20170421
- International Application: PCT/CN2018/083746 WO 20180419
- International Announcement: WO2018/192550 WO 20181025
- Main IPC: A61K47/64
- IPC: A61K47/64 ; A61K47/60 ; A61K47/65 ; A61P35/00 ; A61K31/4745

Abstract:
A multi-branched drug conjugate of formula (I) or a pharmaceutically acceptable salt thereof. In the formula, R is an organic center, POLY is a polymer, L is a multivalent linker, T is a targeting molecule, D is an active agent, and q is any integer between 3 and 8. The symbol “*” in L represents a junction point of the multivalent linker L and the targeting molecule T, “#” represents a junction point of the multivalent linker L and the active agent D, and “%” represents a junction point of the multivalent linker L and POLY. 1 is any integer between 2 and 20, and m and n are each an integer between 0 and 10. T is iRGD, cRGD, tLyp-1, Lyp-1, RPARPAR, Angiopep2, or GE11. D is a camptothecin drug.
Public/Granted literature
- US20210008218A1 MULTI-ARM TARGETING ANTI-CANCER CONJUGATE Public/Granted day:2021-01-14
Information query
IPC分类: